GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (OTCPK:ACHKF) » Definitions » Notes Receivable

Achiko AG (Achiko AG) Notes Receivable : $0.00 Mil (As of Jun. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Achiko AG Notes Receivable?

Achiko AG's Notes Receivable for the quarter that ended in Jun. 2022 was $0.00 Mil.


Achiko AG Notes Receivable Historical Data

The historical data trend for Achiko AG's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achiko AG Notes Receivable Chart

Achiko AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Notes Receivable
- - - -

Achiko AG Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Notes Receivable Get a 7-Day Free Trial - - - - -

Achiko AG Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Achiko AG Notes Receivable Related Terms

Thank you for viewing the detailed overview of Achiko AG's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Achiko AG (Achiko AG) Business Description

Traded in Other Exchanges
N/A
Address
Tessinerplatz 7, Zurich, CHE, CH-8002
Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.